

Nano One Materials Corp.

Condensed Interim Consolidated Financial Statements

For the six months ended

June 30, 2024

(Unaudited – Prepared by Management) (Expressed in Canadian dollars)

NOTICE OF NO AUDITOR REVIEW OF THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

The accompanying condensed interim consolidated financial statements of Nano One Materials Corp. ("the Company") as at and for the six months ended June 30, 2024, have been prepared by the management of the Company and approved by the Company's Audit Committee.

Under National Instrument 51-102, Part 4, subsection 4.3 (3) (a), if an auditor has not performed a review of the interim financial statements, they must be accompanied by a notice indicating that an auditor has not reviewed the financial statements.

The accompanying condensed interim consolidated financial statements of the Company have been prepared by and are the responsibility of the Company's management. The Company's independent auditor has not performed a review of these financial statements in accordance with standards established by CPA Canada for a review of condensed interim financial statements by an entity's auditor.

Condensed Interim Consolidated Statements of Financial Position

Unaudited – Prepared by Management

(Expressed in Canadian Dollars)

As at June 30, 2024 and December 31, 2023

		June 30, 2024	December 31, 2023
	Note	\$	\$
Assets			
Current assets			
Cash and cash equivalents	10	15,142,843	31,868,882
Restricted cash	10	575,000	575,000
Receivables and prepayments	3	1,506,541	1,130,043
Inventory	4	410,436	705,278
·		17,634,820	34,279,203
Non-current assets		·	
Deposits and other assets	3	386,453	295,411
Property, plant and equipment	5	18,219,186	18,362,255
Intangible assets - patents	6	43,131	37,899
·		18,648,770	18,695,565
Total assets		36,283,590	52,974,768
Liabilities and shareholders' equity			
Current liabilities			
Accounts payable and accrued liabilities	9	3,948,162	3,723,265
Accounts payable to related parties	9	20,850	46,461
Lease liabilities - current portion	5	435,836	374,242
		4,404,848	4,143,968
Non-current liabilities			
Lease liabilities	5	1,119,050	1,344,144
Total liabilities		5,523,898	5,488,112
Shareholders' equity			
Share capital	8	125,120,773	125,042,258
Reserves	8	5,274,384	7,171,841
Deficit		(99,635,465)	(84,727,443
Total shareholders' equity		30,759,692	47,486,656
Total liabilities and shareholders' equity		36,283,590	52,974,768

Nature of operations and going concern 1
Subsequent events 14

Approved on behalf of the Board of Directors on August 13, 2024:

"Carla Matheson"	"Lyle Brown"
Director	Director

Condensed Interim Consolidated Statements of Loss and Comprehensive Loss

Unaudited – Prepared by Management

(Expressed in Canadian Dollars)

For the three and six months ended June 30, 2024 and June 30, 2023

		Three months ended		Six months ended	
		June 30, 2024	June 30, 2023	June 30, 2024	June 30, 2023
	Note	\$	\$	\$	\$
Expenses					
Amortization	6	909	668	1,727	1,301
Business development and investor relations		237,878	207,500	335,896	352,847
Depreciation	5	67,909	61,552	134,054	119,739
Finance costs	5	47,838	26,988	98,036	51,644
General and administrative expenses		644,861	619,031	1,338,483	1,287,185
Professional and consulting, net	9	604,601	646,631	1,187,196	1,249,572
Research and operational expenses, net	7	2,446,718	2,054,305	5,066,812	3,999,381
Share-based payments	8,9	403,093	445,824	1,668,806	667,274
Wages, benefits and fees, net	9	4,164,090	4,026,072	9,175,894	8,843,991
Loss from operating expenses		(8,617,897)	(8,088,571)	(19,006,904)	(16,572,934)
Interest income	11	214,111	401,793	559,748	819,874
Loss on disposal of equipment		-	(964)	(25,603)	(10,786)
Other income		34,006	-	76,989	-
Loss and comprehensive loss for the period		(8,369,780)	(7,687,742)	(18,395,770)	(15,763,846)
Loss per share Weighted average number of common shares outstanding					
- basic		111,288,901	103,272,342	111,277,718	102,674,854
- diluted		111,288,901	103,272,342	111,277,718	102,674,854
Basic loss per common share		(80.0)	(0.07)	(0.17)	(0.15)
Diluted loss per common share		(0.08)	(0.07)	(0.17)	(0.15)

Condensed Interim Consolidated Statements of Cash Flows

Unaudited – Prepared by Management

(Expressed in Canadian Dollars)

For the six months ended June 30, 2024 and June 30, 2023

		June 30, 2024	June 30, 2023
	Note	\$	\$
Operating activities			
Loss for the period		(18,395,770)	(15,763,846)
Adjustments for:		(.0,000,)	(10,100,010)
Amortization		1,727	1,301
Depreciation	5	746.518	681,044
Finance costs		98.036	51,644
Share-based payments		1,668,806	667,274
Interest income		(559,748)	(819,874)
Loss on disposal of equipment		25,603	10,786
Net change in non-cash working capital items	10	822,720	4,070,337
		(15,592,108)	(11,101,334)
Investing activities			
Interest income received on cash and cash equivalents		559,748	819,874
Deposits and other assets		559,740	(488,308)
Purchases of property, plant and equipment, net		(1,425,184)	(854,624)
Payments for intangible assets	6	(6,959)	(4,231)
- Taymonia for mangiore associa	0	(872,395)	(527,289)
			_
Financing activities			
Issuance of common shares for cash		-	6,777,245
Payments of lease liabilities	5	(261,536)	(190,880)
		(261,536)	6,586,365
Change in cash and cash equivalents		(16,726,039)	(5,042,258)
Cash and cash equivalents, beginning of period		31,868,882	39,445,395
Cash and cash equivalents, end of period		15,142,843	34,403,137

Supplemental cash flow information

Condensed Interim Consolidated Statements of Changes in Shareholders' Equity

Unaudited – Prepared by Management

(Expressed in Canadian Dollars)

For the six months ended June 30, 2024 and June 30, 2023

	Number of	Share capital	Shares committed for issuance	Reserves	Deficit	Total
	common shares	\$	\$	\$	\$	\$
B 1 04 0000	400 540 405	00 704 474	474.000	40.000.000	(50.005.000)	50.440.000
December 31, 2022	100,516,495	96,704,471	171,000	10,209,880	(53,635,982)	53,449,369
Exercise of RSUs	86,409	302,712	-	(302,712)	-	-
Exercise of stock options	1,444,446	3,297,143	(171,000)	-	-	3,126,143
Exercise of stock options - cashless net exercise	12,776	-	-	-	-	-
Re-allocated on exercise of stock options	-	1,707,629	-	(1,707,629)	-	-
Re-allocated on cancellation of stock options	-	-	-	(63,022)	63,022	-
Exercise of warrants	2,281,939	3,651,102	-	-	-	3,651,102
Re-allocated on exercise of warrants	-	22,013	-	(22,013)	-	-
Re-allocated on expiry of warrants	-	909	-	(595,909)	595,000	-
Share-based payments	-	-	-	667,274	-	667,274
Loss and comprehensive loss for the period	-	-	-	-	(15,763,846)	(15,763,846)
June 30, 2023	104,342,065	105,685,979	-	8,185,869	(68,741,806)	45,130,042
December 31, 2023	111,266,777	125,042,258	_	7,171,841	(84,727,443)	47,486,656
Exercise of RSUs	25,205	78,515	-	(78,515)	-	
Re-allocated on cancellation/expiry of stock options	· -	-	-	(3,474,381)	3,474,381	-
Re-allocated on cancellation of RSUs	-	-	-	(13,367)	13,367	-
Share-based payments	-	-	-	1,668,806	-	1,668,806
Loss and comprehensive loss for the period				<u>-</u>	(18,395,770)	(18,395,770)
June 30, 2024	111,291,982	125,120,773	-	5,274,384	(99,635,465)	30,759,692

Notes to the Condensed Interim Consolidated Financial Statements

Unaudited – Prepared by Management

(Expressed in Canadian Dollars)

For the six months ended June 30, 2024 and June 30, 2023

1. NATURE OF OPERATIONS AND GOING CONCERN

Nano One® Materials Corp. (the "Company") was incorporated under the laws of the Province of Alberta on November 5, 1987 and continued under the laws of the Province of British Columbia. The Company's head office is located at Unit 101B - 8575 Government Street, Burnaby, BC, V3N 4V1, Canada. Its records office is located at Suite 2900 – 550 Burrard Street, Vancouver, BC, V6C 0A3, Canada. The Company's common shares trade on the Toronto Stock Exchange (the "TSX") under the symbol "NANO".

The Company has patented (Note 6) and scaled-up an innovative "One-Pot process" for the production of cathode active materials (CAM) for lithium-ion battery applications in electric vehicles, energy storage systems, and consumer electronics.

These unaudited condensed interim consolidated financial statements (the "financial statements") have been prepared on a going concern basis which contemplates that the Company will be able to continue its operations for at least twelve months from June 30, 2024 and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business. The Company has not generated revenue from operations to date and will require additional financing or outside participation to further advance is strategic initiatives. Future operations of the Company are dependent upon its ability to raise additional equity financing and seek government subsidies and maintain sufficient working capital and upon future revenues from offtakes.

As of June 30, 2024, the Company had cash and cash equivalents of \$15,142,843 (December 31, 2023 - \$31,868,882) a working capital of \$13,229,972 (December 31, 2023 - \$30,135,235), which is calculated as current assets less current liabilities, and an accumulated deficit of \$99,635,465 (December 31, 2023 - \$84,727,443). For the six months ended June 30, 2024, the Company incurred a net loss of \$18,395,770 and used cash in operating activities of \$15,592,108. The Company's operations to date have been financed by the issuance of common shares, various government fundings, and the exercise of stock options and warrants. The continuing operations of the Company are dependent upon its ability to continue to raise adequate financing and liquidate assets as necessary. Despite this, there can be no assurance that the Company will be able to continue securing additional financings in the future, and if they are secured, that they would be on terms favourable to the Company. This gives rise to a material uncertainty that may raise substantial doubt about the Company's ability to continue as a going concern. These financial statements do not give effect to any adjustments to the carrying values of the assets and liabilities, the reported expenses, and the statements of financial position classifications used that would be necessary should the Company be unable to continue as going concern. Such adjustments could be material.

2. MATERIAL ACCOUNTING POLICY INFORMATION

Basis of presentation

These financial statements have been prepared in conformity with International Accounting Standard ("IAS") 34, Interim Financial Reporting, using the same accounting policy information as detailed in the Company's annual audited financial statements for the year ended December 31, 2023, and do not include all the information required for full annual financial statements in accordance with IFRS Accounting Standards ("IFRS"), as issued by the International Accounting Standards Board ("IASB"). It is suggested that these financial statements be read in conjunction with the annual audited consolidated financial statements.

These financial statements have been prepared on a historical cost basis, except for financial instruments measured at fair value. In addition, these financial statements have been prepared using the accrual basis of accounting, except for cash flow information.

Functional and presentation currency

All amounts on these financial statements are presented in Canadian dollars which is the functional currency of the Company and its subsidiaries.

Notes to the Condensed Interim Consolidated Financial Statements

Unaudited - Prepared by Management

(Expressed in Canadian Dollars)

For the six months ended June 30, 2024 and June 30, 2023

2. MATERIAL ACCOUNTING POLICY INFORMATION (continued)

Principles of consolidation

These financial statements include the financial information of the Company and its subsidiaries.

The financial statements include the following entities:

Nano One Materials Corp.

Nano One Materials Québec Inc. ("Nano Québec")

Nano One Materials Candiac Inc. ("Nano Candiac")

100%

Parent company
Holding company
Operating subsidiary

Subsidiaries are entities controlled by the Company and are included in the financial statements from the date that control commences until the date that control ceases. The accounting policies of subsidiaries are changed where necessary to align them with the policies adopted by the Company. Inter-company balances and transactions, and any unrealized income (loss) and expenses arising from inter-company transactions, are eliminated in preparing the financial statements.

Material accounting policies

Except as noted below, the accounting policies, estimates and critical judgments, methods of computation and presentation applied in these financial statements are consistent with those of the most recent annual audited consolidated financial statements and are those the Company expects to adopt in its annual audited consolidated financial statements for the year ended December 31, 2024. Accordingly, these financial statements should be read in conjunction with the Company's most recent annual audited financial statements.

During the six months ended June 30, 2024, the Company changed certain estimates over the depreciation of property, plant and equipment on a prospective basis. Effective January 1, 2024, certain of the Company's production and equipment fixtures are being depreciated on a straight-line basis between five (5) and ten (10) years (formerly 20% declining balance basis); and certain information technology equipment are being depreciated on a straight-line basis over three (3) years (formerly 30% declining balance basis).

New accounting policies

Certain pronouncements have been issued by the IASB that are effective for the Company's accounting period beginning on January 1, 2024. The Company has reviewed all other updates and determined that none are applicable or consequential to the Company and have been excluded from discussion within the material accounting policy information.

Standards issued but not yet effective

In June 2023, the International Sustainability Standards Board ("ISSB") issued the following IFRS Sustainability Disclosure Standards: *General Requirements for Disclosure of Sustainability-related Information* (IFRS S1); and *Climate-related Disclosure* (IFRS S2), which are effective for accounting periods beginning on or after January 1, 2024, but are not currently mandated in Canada. The Company will monitor the continued development of mandating these standards and the requisite disclosure requirements.

IFRS S1 sets out general reporting requirements for disclosing sustainability-related financial information. IFRS S2 requires an entity to disclose information about climate-related risks and opportunities and the impact on an entity's financial position, performance, cash flows, strategy, and business model.

Notes to the Condensed Interim Consolidated Financial Statements

Unaudited – Prepared by Management

(Expressed in Canadian Dollars)

For the six months ended June 30, 2024 and June 30, 2023

3. RECEIVABLES AND PREPAYMENTS, DEPOSITS AND OTHER ASSETS

Receivables and prepayments consist of the following:

	June 30,	December 31,
	2024	2023
	\$	\$
Accrued government assistance	15,000	10,833
Prepaid expenses	833,855	738,333
Sales tax recoverable and other	657,686	380,877
	1,506,541	1,130,043

Research cost recoveries

During the six months ended June 30, 2024 and June 30, 2023, the Company accrued or received the following cost recoveries within research and operational expenses, net:

	June 30,	June 30,
	2024	2023
	\$	\$
USCo	-	161,700

American-based multinational auto manufacturer ("USCo"):

In 2020, the Company entered into a Cathode Evaluation Agreement with USCo to jointly evaluate the performance and commercial benefit of the Company's patented process for nickel-rich and cobalt-free cathode materials in lithium-ion batteries for electric vehicle applications. The parties continue to collaborate under this arrangement.

During the six months ended June 30, 2024, there were no cost recoveries recognized or received from USCo. During the six months ended June 30, 2023, the Company invoiced USCo for future services totalling \$161,700 (US\$122,500).

Deposits and other assets

Deposits and other assets consist of the following:

	June 30,	December 31,
	2024	2023
	\$	\$
Spare parts and deposits on property, plant and equipment	193,880	102,838
Security and other deposits	192,573	192,573
	386.453	295.411

4. INVENTORY

Inventory is comprised of the following:

	June 30,	December 31,
	2024	2023
	\$	\$
Raw materials	396,890	701,932
Packaging	2,774	-
Inventory - work in progress	10,772	3,346
	410,436	705,278

Notes to the Condensed Interim Consolidated Financial Statements

Unaudited – Prepared by Management

(Expressed in Canadian Dollars)

For the six months ended June 30, 2024 and June 30, 2023

5. PROPERTY, PLANT AND EQUIPMENT

	Production and research equipment \$	Building \$	Land \$	Right-of-use assets \$	Leasehold improvements \$	Construction in progress	Information technology equipment \$	Pilot plant \$	Total \$
Cost									
December 31, 2022	5,045,390	4,874,961	3,263,658	1,184,752	265,083	220,338	472,142	2,219,529	17,545,853
Additions, net	2,805,836	-	-	1,241,138	579,244	2,382,186	136,009	-,,	7,144,413
Reclass	2,602,524	_	-	-	-	(2,602,524)	-	_	
Disposal	(341,468)	_	-	_	-	-	(1,014)	_	(342,482)
December 31, 2023	10,112,282	4,874,961	3,263,658	2,425,890	844,327	-	607,137	2,219,529	24,347,784
Accumulated depreciation									
December 31, 2022	1,339,711	31,418	-	534,779	163,741	-	215,565	2,219,529	4,504,743
Depreciation	668,791	194,998	-	371,192	147,308	-	121,104	-	1,503,393
Disposal	(22,560)	· -	-	· -	· -	-	(47)	-	(22,607)
December 31, 2023	1,985,942	226,416	-	905,971	311,049	-	336,622	2,219,529	5,985,529
Cost									
December 31, 2023	10,112,282	4,874,961	3,263,658	2,425,890	844,327	-	607,137	2,219,529	24,347,784
Additions, net	137,233	-	-	-	152,211	334,524	5,084	-	629,052
Disposals	(28,298)	-	-	-	-	-	-	-	(28,298)
June 30, 2024	10,221,217	4,874,961	3,263,658	2,425,890	996,538	334,524	612,221	2,219,529	24,948,538
Accumulated depreciation									
December 31, 2023	1,985,942	226,416	-	905,971	311,049	-	336,622	2,219,529	5,985,529
1) Depreciation	343,358	97,499	-	228,903	31,053	-	45,705	-	746,518
Disposals	(2,695)	-	-	-	-	-	-	-	(2,695)
June 30, 2024	2,326,605	323,915	-	1,134,874	342,102	-	382,327	2,219,529	6,729,352
Net book value									
December 31, 2023	8,126,340	4,648,545	3,263,658	1,519,919	533,278	-	270,515	-	18,362,255
June 30, 2024	7,894,612	4,551,046	3,263,658	1,291,016	654,436	334,524	229,894	-	18,219,186

⁽¹⁾ Depreciation for the six months ended June 30, 2024 and June 30, 2023, is allocated as follows:

	Depreciation	operational	Total	
	expense	expenses, net		
	\$	\$	\$	
Production and research equipment	-	311,897	311,897	
Building	-	97,499	97,499	
Right-of-use assets	51,642	97,371	149,013	
Leasehold improvements	12,261	54,538	66,799	
Information technology equipment	55,836	-	55,836	
June 30, 2023	119,739	561,305	681,044	
Production and research equipment	-	343,358	343,358	
Building	-	97,499	97,499	
Right-of-use assets	71,908	156,995	228,903	
Leasehold improvements	16,441	14,612	31,053	
Information technology equipment	45,705	-	45,705	
June 30, 2024	134,054	612,464	746,518	

Notes to the Condensed Interim Consolidated Financial Statements

Unaudited – Prepared by Management

(Expressed in Canadian Dollars)

For the six months ended June 30, 2024 and June 30, 2023

5. PROPERTY, PLANT AND EQUIPMENT (continued)

Net additions to property, plant and equipment include amounts amortized from deferred government assistance which reduces gross additions. For the six months ended June 30, 2024 and the year ended December 31, 2023, these amounts were allocated within property, plant and equipment as follows:

	June 30,	December 31,
	2024	2023
	\$	\$
Production and research equipment	-	2,217,832

Right-of-use assets and Lease liabilities

The Company has agreements to lease certain of its offices and research facilities. The Company has determined that its lease contracts are leases as defined under IFRS 16 *Leases* ("IFRS 16"). In analyzing the identified contracts, the Company applied the lessee accounting model pursuant to IFRS 16 and considered all the facts and circumstances surrounding the inception of the contract (but not future events that are not likely to occur). Lease liabilities have been calculated at initial recognition with a discount rate of either 9% or 12%.

The Company has identified the following leases:

Location	Asset	Туре	Term of lease at June 30, 2024 inluding extensions (years)
Burnaby, BC	Building	Corporate head office (extension)	4.2
Burnaby, BC	Building	Research facilities	4.2
Burnaby, BC	Building	Warehouse and office	1.6
Burnaby, BC	Building	Corporate head office (main)	1.3

A reconciliation of the carrying amount of the lease liabilities as at June 30, 2024 and December 31, 2023, and changes during the period/year then ended is as follows:

	June 30, 2024	December 31, 2023
Lease liabilities		
Lease liabilities	\$	\$
Beginning of period/year	1,718,386	773,917
Addition or extension	-	1,241,138
Lease payments	(261,536)	(457,001)
Lease interest (finance costs)	98,036	160,332
End of period/year	1,554,886	1,718,386
Current portion of lease liabilities	435,836	374,242
Non-current portion of lease liabilities	1,119,050	1,344,144
Maturity analysis - contractual undiscounted cash flows		
Less than one year	597,973	559,687
One to five years	1,341,547	989,809
More than five years	-	651,560
Total undiscounted lease liabilities	1,939,520	2,201,056

Short-term leases are leases with a lease term of twelve months or less. As at June 30, 2024 and December 31, 2023, the Company did not have any short-term leases. As at June 30, 2024, the Company included the available extension options on its leases within the measurement of the lease liabilities, and there were no leases with residual value guarantees.

Notes to the Condensed Interim Consolidated Financial Statements

Unaudited – Prepared by Management

(Expressed in Canadian Dollars)

For the six months ended June 30, 2024 and June 30, 2023

6. INTANGIBLE ASSETS

As at June 30, 2024, intangible assets included various patents that were approved for issuance, or have issued, associated with the Company's technology. These patents were issued by various jurisdictions including Canada, China, India, Japan, Korea, Taiwan, and the United States. The patents have expiries ranging between ten (10) to nineteen (19) years from the patent issuance date.

The amount capitalized as intangible assets represents only the patent issue costs. Application, renewal, and other costs are expensed to professional and consulting, as incurred. The Company has other pending patent applications in which all associated costs have been expensed.

	Issued patents \$
Cost	
December 31, 2022	38,846
Additions	9,169
December 31, 2023	48,015
Accumulated amortization	
December 31, 2022	7,109
Amortization	3,007
December 31, 2023	10,116
Cost	
December 31, 2023	48,015
Additions	6,959
June 30, 2024	54,974
Accumulated amortization	
December 31, 2023	10,116
Amortization	1,727
June 30, 2024	11,843
Net book value	
December 31, 2023	37,899
June 30, 2024	43,131

Notes to the Condensed Interim Consolidated Financial Statements

Unaudited - Prepared by Management

(Expressed in Canadian Dollars)

For the six months ended June 30, 2024 and June 30, 2023

7. GOVERNMENT ASSISTANCE

The Company receives funding from various Canadian federal and provincial government programs. During the six months ended June 30, 2024 and June 30, 2023, the following amounts were received:

		June 30,	June 30,
		2024	2023
	Amounts received:	\$	\$
(1)	Sustainable Development Technology Canada (SDTC)	-	3,284,507
(2)	Industrial Research Assistance Program (NRC-IRAP)	18,334	77,407
(2)	Other Grants	68,417	33,865
		86,751	3,395,779

- (1) See deferred government assistance below for allocation of SDTC proceeds for the six months ended June 30, 2024.
- (2) Proceeds are recorded within research and operational expenses, net.

Deferred government assistance (deferred liabilities):

As at June 30, 2024 and December 31, 2023, deferred liabilities included amounts for deferred government assistance in relation to SDTC projects. A reconciliation of the carrying amount of the deferred government assistance as at June 30, 2024 and December 31, 2023, and changes during the period/year then ended are as follows:

		June 30,	December 31,
		2024	2023
	Deferred government assistance	\$	\$
	Beginning of period/year	-	-
	Additions - proceeds received	-	3,284,507
(1)	Amortization	-	(3,284,507)
	End of period/year	-	-

(1) Amortization of deferred government assistance is allocated as follows:

	June 30,	June 30, 2023	
	2024		
	\$	\$	
Property, plant and equipment	-	974,862	
Research and operational expenses, net	-	504,001	
Wages, benefits and fees, net	-	260,306	
	-	1,739,169	

Sustainable Development Technology Canada ("SDTC"):

SDTC Pre-Commercial Trial and Multi Cathode Piloting Hub Project (active):

On February 13, 2023, the Company executed an agreement with SDTC in respect of a new government program (Pre-Commercial Trial and Multi Cathode Piloting Hub) (the "SDTC Pre-Commercial Project") which will provide the Company up to \$10,000,000 (\$3,284,507 received as at June 30, 2024 and December 31, 2023) in funding from SDTC in stages. The funds are non-dilutive, and non-repayable and are intended to support the Company's design, construction, and operation of a multi-cathode piloting hub in Candiac. The initial project timeline is from January 1, 2023 to December 31, 2025.

The funds from the SDTC Pre-Commercial Project will be paid to the Company in four (4) instalments plus the release of a final 10% hold-back upon satisfactory review and approval of the project by SDTC. The instalments from SDTC will be paid to the Company at the beginning of each of the four (4) Milestones and will be initially recognized within deferred liabilities.

During the year ended December 31, 2023, the Company received Milestone 1 funds of \$3,284,507.

Notes to the Condensed Interim Consolidated Financial Statements

Unaudited – Prepared by Management

(Expressed in Canadian Dollars)

For the six months ended June 30, 2024 and June 30, 2023

7. GOVERNMENT ASSISTANCE (continued)

SDTC Scaling Project (completed):

In 2019, the Company executed a contribution agreement with SDTC for a non-repayable grant in respect of the Company's "Scaling Advanced Battery Materials" project (the "SDTC Scaling Project"). The SDTC Scaling Project grant was for \$8,545,500 (received) which includes British Columbia Innovative Clean Energy, Mines and Petroleum Resources ("BC-ICE") contributions (discussed below).

As at December 31, 2023, all proceeds had been received including the final holdback of \$803,300 received during the year ended December 31, 2023.

As at December 31, 2023, the Company had completed this project along with its reporting obligations to SDTC.

National Research Council of Canada's Industrial Research Assistance Program ("NRC-IRAP"):

Between the programs detailed below, the Company received proceeds from NRC-IRAP during the six months ended June 30, 2024, of \$18,334 (2023 - \$77,407).

Youth Internship Contribution Agreement (active):

Since 2021, the Company has entered into various Youth Internship Contribution Agreements with NRC-IRAP. Under the terms of the agreements, the contributions from NRC-IRAP were for the reimbursement of certain salaries paid to employees of the Company.

M2CAM Program (completed):

In 2021, the Company executed an agreement with NRC-IRAP for non-repayable contributions to the Company totalling \$439,000 over the course of the program through to June 2023 (completed). The scope of the program was research into cost optimization of the Company's patented process for the manufacture of cathode active materials and specifically the use of metal feedstocks and thermal processing methods (M2CAM). Under the terms of the agreement, NRC-IRAP reimbursed the Company for 80% of salaries paid to employees involved in this project.

The cumulative amounts of grant funding received since 2014 from the Government of Canada are as follows:

	June 30,	December 31,	
	2024	2023	
	\$	\$	
SDTC and BC-ICE	13,911,314	13,911,314	
NRC-IRAP ⁽¹⁾	1,585,331	1,566,997	
Other Grants	2,260,954	2,192,537	
	17,757,599	17,670,848	

⁽¹⁾ Includes amounts from the Innovation Assistance Program (IAP) from NRC-IRAP.

Scientific Research and Experimental Development ("SR&ED"):

During the six months ended June 30, 2024, the Company claimed refundable SR&ED amounts in relation to Nano Candiac for the year ended December 31, 2023 and the period from November 1, 2022 to December 31, 2022. As at June 30, 2024, \$310,879 was accrued (December 31, 2023 - \$nil) as receivable, with offsetting credits recorded against subcontractor costs and employee wages which are aggregated within wages, benefits and fees. The SR&ED claim is subject to review and approval by the Canada Revenue Agency (CRA).

Notes to the Condensed Interim Consolidated Financial Statements

Unaudited – Prepared by Management

(Expressed in Canadian Dollars)

For the six months ended June 30, 2024 and June 30, 2023

8. SHARE CAPITAL AND RESERVES

The authorized share capital of the Company consists of unlimited common shares without par value. All issued common shares are fully paid.

Share capital

Transactions for the issuance of share capital during the six months ended June 30, 2024:

a) In April 2024, upon the exercise of RSUs, 25,205 common shares were issued for \$nil proceeds. In addition, \$78,515 representing the fair value initially recognized, was re-allocated from reserves to share capital.

Transactions for the issuance of share capital during the six months ended June 30, 2023:

- a) Upon the exercise of RSUs, 86,409 common shares were issued for \$nil proceeds. In addition, \$302,712 representing the fair value initially recognized, was re-allocated from reserves to share capital.
- b) Upon the exercise of stock options, 1,444,446 common shares were issued at prices between \$1.14 and \$2.88 each for proceeds of \$3,126,143 (\$3,297,143 gross proceeds, less \$171,000 which had been collected as at December 31, 2022. In addition, \$1,707,629 representing the fair value initially recognized, was re-allocated from reserves to share capital.
 - Additionally, the Company issued 12,776 common shares on the cashless net exercise of 97,500 stock options which were exercisable at \$2.52 each. The re-allocation of the fair value initially recognized is combined within the amount disclosed above.
- c) Upon the exercise of warrants, 2,281,939 common shares were issued at \$1.60 each for proceeds of \$3,651,102. In addition, \$22,013 representing the fair value initially recognized, was re-allocated from reserves to share capital.

Reserves

The Company has an Omnibus Equity Incentive Plan which was approved by shareholders in 2021 (the "Equity Plan"). The Equity Plan provides for the grant of stock options, RSUs, DSUs, performance share units ("PSUs") and other share-based awards subject to TSX approval. Under the Equity Plan, the maximum number of equity-based awards issued cannot exceed 10% of the Company's currently issued and outstanding common shares. Additionally, RSUs are required to be settled by December 31 in the third year following the year of grant ("Expiry date"), whereas DSUs are settled once the awardee retires or departs.

Stock options

In accordance with the Equity Plan, the exercise price of each stock option shall not be less than the market price of the Company's common shares as calculated at the close of the trading session on the date immediately prior to the date of grant. Stock options can be granted for a maximum term of ten years, and vest at the discretion of the Board of Directors. Stock options outstanding under the Company's former stock option plan are governed by the Equity Plan unless the former stock option plan is more beneficial, in which case the terms of the stock option plan will apply for the benefit of the option holder. The Company's Equity Plan permits the holder of stock options to exercise cashless (net exercise) by surrendering a portion of the underlying stock option shares to pay for the exercise cost.

Notes to the Condensed Interim Consolidated Financial Statements

Unaudited - Prepared by Management

(Expressed in Canadian Dollars)

For the six months ended June 30, 2024 and June 30, 2023

8. SHARE CAPITAL AND RESERVES (continued)

Stock options (continued)

A summary of the status of the Company's stock options as at June 30, 2024 and December 31, 2023, and changes during the period/year then ended is as follows:

	Period ended June 30, 2024		Year ended December 31, 2023	
	Weighted average Options exercise price		Options	Weighted average exercise price
	#	\$	#	\$
Options outstanding, beginning of period/year	2,688,565	4.48	6,269,863	2.80
Granted	943,948	1.92	452,418	3.28
Exercised	-	-	(3,955,321)	1.70
Cancelled/expired	(1,420,988)	5.09	(78,395)	3.28
Options outstanding, end of period/year	2,211,525	2.99	2,688,565	4.48

As at June 30, 2024, the Company has stock options outstanding and exercisable as follows:

Options	Options	Exercise	
outstanding	exercisable	price	Expiry date
#	#	\$	
40,000	40,000	3.62	October 5, 2024
240,000	240,000	3.14	December 2, 2024
400,000	400,000	5.10	February 1, 2026
139,263	93,025	2.88	February 4, 2027
9,100	9,100	2.88	June 13, 2027
439,214	146,690	3.28	March 17, 2028
200,000	-	1.94	January 19, 2029
743,948	500,000	1.91	January 23, 2031
2,211,525	1,428,815	2.99	

The following table summarizes the above information about the stock options outstanding as at June 30, 2024:

Exercise		Weighted average	Weighted average
prices	Options	remaining life	exercise price
\$	#	(years)	\$
1.91 - 2.88	1,092,311	5.7	2.05
3.14 - 3.62	719,214	2.4	3.25
5.10	400,000	1.6	5.10
	2,211,525	3.9	2.99

The Company recorded the fair value of the stock options granted during the six months ended June 30, 2024 and June 30, 2023, using the Black-Scholes option pricing model. The fair value is particularly impacted by the Company's stock price volatility. The fair values were determined using the following weighted average assumptions:

	June 30,		June 30,	
		2024		2023
Risk-free interest rate		3.5%		2.9%
Expected life of stock options (years)		6.6		5.0
Historical volatility		74.0%		77.2%
Dividend rate		0.0%		0.0%
Weighted average fair value per stock option granted	\$	1.33	\$	2.10

Notes to the Condensed Interim Consolidated Financial Statements

Unaudited - Prepared by Management

(Expressed in Canadian Dollars)

For the six months ended June 30, 2024 and June 30, 2023

8. SHARE CAPITAL AND RESERVES (continued)

Stock options (continued)

The total share-based payments expense for the six months ended June 30, 2024, was \$1,668,806 (2023 - \$667,274), of which \$1,042,441 (2023 - \$283,788) was attributable to vesting of stock options during the period then ended.

During the period ended June 30, 2024, 1,420,988 (2023 – 32,582) stock options were either cancelled/forfeited upon certain individuals leaving employment of the Company or expired unexercised. As a result, the original share-based payments expense of \$3,474,381 (2023 - \$63,022) was reversed from reserves and credited to deficit.

Restricted share units and deferred share units (RSUs / DSUs)

In accordance with the Equity Plan, RSUs and DSUs are granted to directors, officers, employees, and consultants as part of long-term incentive compensation. The number of Equity Incentives awarded, and underlying vesting conditions are determined by the Company. Additionally, at the Company's sole discretion, upon each vesting date participants receive (a) common shares equal to the number of Equity Incentives that vested; (b) a cash payment equal to the number of vested Equity Incentives multiplied by the fair market value of a Voting Share; or (c) a combination of (a) and (b).

On the grant date of RSUs and DSUs, the Company determines whether it has a present obligation to settle in cash. If the Company has a present obligation to settle in cash, the RSUs and DSUs are accounted for as liabilities, with the fair value remeasured at the end of each reporting period and at the date of settlement, with any changes in fair value recognized in profit or loss for the period. The Company has a present obligation to settle in cash if the Company has a past practice or a stated policy of settling in cash, or generally settles in cash whenever the counterparty asks for cash settlement. If no such obligation exists, RSUs and DSUs are accounted for as equity settled share-based payments and are valued using the share price of the common shares on the grant date.

Since the Company controls the settlement, the RSUs and DSUs are considered equity settled. Additionally, upon vesting of RSUs, the Company has a commitment to settle vested RSUs in the form of issuing common shares to the holders in equity settled arrangements.

Pursuant to the underlying agreements, all Equity Incentives granted to the date of approval of these financial statements are expected to be settled in common shares.

A summary of the status of the Company's Equity Incentives as at June 30, 2024 and December 31, 2023, and changes during the period/year then ended is as follows:

	Period ended June 30, 2024	Year ended December 31, 2023
	Equity Incentives	Equity Incentives
	#	#
Equity Incentives outstanding, beginning of period/year	667,774	379,679
Granted - RSUs	622,738	237,109
Granted - DSUs	-	182,550
Exercised	(25,205)	(131,564)
Cancelled	(6,855)	<u>-</u>
Equity Incentives outstanding, end of period/year	1,258,452	667,774

Notes to the Condensed Interim Consolidated Financial Statements

Unaudited - Prepared by Management

(Expressed in Canadian Dollars)

For the six months ended June 30, 2024 and June 30, 2023

8. SHARE CAPITAL AND RESERVES (continued)

Restricted share units and deferred share units (RSUs / DSUs) (continued)

As at June 30, 2024, the Company has RSUs and DSUs outstanding as follows:

RSUs	RSUs	DSUs	Weighted average		
outstanding	Exercisable	outstanding	grant date fair value		
#	#	#	per RSU/DSU	Final vesting date	Expiry date
94,727	33,225	-	4.17	August 27, 2024	December 31, 2024
-	-	8,626	4.17	August 27, 2024	n/a
134,369	71,228	-	2.88	February 4, 2025	December 31, 2025
210,996	60,457	-	3.28	March 17, 2026	December 31, 2026
-	-	85,976	3.28	March 17, 2026	n/a
11,301	-	-	2.92	October 10, 2026	December 31, 2026
-	-	96,574	2.92	October 10, 2023	n/a
440,448	-	-	1.95	January 22, 2027	December 31, 2027
175,435	-	-	1.91	January 23, 2027	December 31, 2027
1,067,276	164,910	191,176	2.73		

On January 22, 2024, the Company granted 447,303 RSUs to employees and consultants of the Company. The RSUs vest in three annual instalments (one-third (149,101) on January 22, 2025; one-third (149,101) on January 22, 2026; and the final one-third (149,101) on January 22, 2027).

On January 23, 2024, the Company granted 175,435 RSUs to officers of the Company. The RSUs vest in three annual instalments (one-third (58,478) on January 23, 2025; one-third (58,478) on January 23, 2026; and the final one-third (58,479) on January 23, 2027).

Subsequent to June 30, 2024, the Company granted RSUs and DSUs to Directors of the Company (Note 14).

During the period ended June 30, 2024, 6,855 (2023 – nil) RSUs were cancelled upon certain individuals leaving employment of the Company. As a result, the original share-based payments expense of \$13,367 (2023 - \$nil) was reversed from reserves and credited to deficit.

In accordance with the Plan, the value of the Equity Incentives granted was based on the closing market price of the Company's common shares on the date preceding the date of grant. During the six months ended June 30, 2024, the Equity Incentives were granted at a weighted average fair value of \$1.94 each for a total value of \$1,207,322, which is being accrued within share-based payment expense over the vesting periods.

During the year ended December 31, 2023, the Company granted 225,808 RSUs to officers and directors of the Company, as well as 85,976 DSUs to certain directors of the Company. The RSUs and DSUs vest in three annual instalments (one-third (103,928) on March 17, 2024; one-third (103,928) on March 17, 2025; and the final one-third (103,928) on March 17, 2026).

Additionally, the Company granted 11,301 RSUs to a director of the Company during the year ended December 31, 2023, which vests in three annual instalments (one-third (3,767) on October 10, 2024; one-third (3,767) on October 10, 2025; and the final one-third (3,767) on October 10, 2026). The Company also granted 96,574 DSUs to directors of the Company which vested immediately.

During the year ended December 31, 2023, the Equity Incentives were granted at a weighted average fair value of \$3.19 each for a total value of \$1,337,647, which is being accrued within share-based payment expense over the vesting periods.

The total share-based payments expense for the six months ended June 30, 2024, was \$1,668,806 (2023 - \$667,274), of which \$626,365 (2023 - \$383,486) represents the vesting of Equity Incentives with the remaining portion of share-based payment expense being attributable to stock options, as described above.

Notes to the Condensed Interim Consolidated Financial Statements

Unaudited - Prepared by Management

(Expressed in Canadian Dollars)

For the six months ended June 30, 2024 and June 30, 2023

8. SHARE CAPITAL AND RESERVES (continued)

Warrants

As an incentive to complete equity financings, the Company may issue units which include common shares and common share purchase warrants. Using the residual value method, the Company determines whether a value should be allocated to warrants attached to units sold in equity financings. Finders' or brokers' warrants may be issued as equity financing share issue costs or for other services and are valued using the Black-Scholes option pricing model.

A summary of the Company's common share purchase warrants as at June 30, 2024 and December 31, 2023, and changes during the period/year then ended is as follows:

		od ended 30, 2024		Year e Decembe	ended r 31, 2023
	Warrants	Weighted ave	•	Warrants	Weighted average exercise price
	#	\$	100	#	\$
Warrants outstanding, beginning of period/year		-	-	3,288,479	2.33
Exercised		-	-	(2,281,939)	1.60
Expired		-	-	(1,006,540)	3.98
Warrants outstanding, end of period/year		-	-	-	-

During the year ended December 31, 2023, certain of the warrants that expired unexercised were issued as compensatory warrants and originally recorded against share capital. As a result, the original fair value on the portion that were compensatory warrants relating to an historical equity financing totaled \$909 and was reversed from reserves and credited to share capital. In addition, 1,000,000 compensatory warrants expired unexercised and their fair value that was originally recorded to operating expenses of \$595,000 was reversed from reserves and credited to deficit.

9. RELATED PARTY TRANSACTIONS

Key management personnel are the persons responsible for the planning, directing, and controlling the activities of the Company and includes both executive and non-executive directors, and entities which key management controls or has significant influence. The Company considers all directors and officers of the Company to be key management.

Termination and Change of Control Benefits

The Company has an executive employment agreement with Dan Blondal, CEO and Director for a base salary of \$348,000 annually. Pursuant to this employment agreement, in the case of termination by the Company without cause, Dan Blondal is entitled to six (6) weeks' base pay (or notice) for every year of service to a maximum of twenty-four (24) months. He would not be entitled to further bonus payments after termination. In the case of resignation after a Change of Control and for Good Reason (as specifically defined), Dan Blondal is entitled to twenty-four (24) months' base salary.

The Company has an executive employment agreement with Alex Holmes, COO, for a base salary of \$295,000 annually. Pursuant to this employment agreement, in the case of termination by the Company without cause, Alex Holmes is entitled to six (6) weeks' base pay (or notice) for every year of service to a maximum of twenty-four (24) months. He would not be entitled to further bonus payments after termination. In the case of resignation after a Change of Control and for Good Reason (as specifically defined), Alex Holmes is entitled to twenty-four (24) months' base salary.

The Company has an arrangement with Paul Matysek, Executive Chairman and Director for a consulting fee of \$150,000 annually, payable to Bedrock Capital Corporation (the "Consultant"), a company controlled by Paul Matysek. In the event of a change of control in the Company, and if within six months of the change of control there is a material change in the Consultant's position as Chairman and Director of the Company, without the Consultant's express consent, the Consultant has the election to terminate the Consulting Agreement within one month following the material change, and the Company shall within 30 days of the election date, make a payment of \$30,000 to the Consultant. Either party may terminate the Consulting Agreement by giving the other party six months' advance written notice of their intention to terminate the Consulting Agreement.

Notes to the Condensed Interim Consolidated Financial Statements

Unaudited – Prepared by Management

(Expressed in Canadian Dollars)

For the six months ended June 30, 2024 and June 30, 2023

9. RELATED PARTY TRANSACTIONS (continued)

The following transactions involved key management (gross amounts):

	Transactions	Transactions	Balances	Balances
	six months ended	six months ended	outstanding	outstanding
	June 30,	June 30,	June 30,	December 31,
	2024	2023	2024	2023
	\$	\$	\$	\$
Bedrock Capital	75,000	75,000	-	-
DBM CPA	7,500	113,000	-	11,550
Directors' fees	161,250	162,759	-	
Management and directors' fees (within wages, benefits and fees)	243,750	350,759	-	11,550
Expense reimbursements (officer)	-	-	1,754	-
Wages, benefits and fees (officers) (1)	1,347,798	1,546,416	-	-
Share-based payments (directors and officers)	1,222,042	413,610	-	-
Patent Filing Specialists (professional and consulting; and intangible assets)	125,162	274,267	19,096	34,911
	2,938,752	2,585,052	20,850	46,461

⁽¹⁾ As at June 30, 2024, accounts payable and accrued liabilities included \$355,435 (December 31, 2023 - \$nil) in accrued short-term incentive compensation to key management relating to 2024 performance which is based on performance targets. Short-term incentive compensation is payable in cash annually during the first quarter of the fiscal year.

During the six months ended June 30, 2024, there were no short-term incentive amounts paid to key management in relation to the year ended December 31, 2023. During the six months ended June 30, 2023, wages benefits and fees included \$599,758 in amounts paid for short-term incentive compensation in relation to 2022.

(a) Professional and consulting, net:

- Includes the services of Patent Filing Specialists Inc. ("Patent Filing Specialists"), a company controlled by Joseph Guy, a Company Director. Transactions are included within both intangible assets (for capitalized patent issue costs) and professional and consulting, net for patent filings, maintenance and related.

(b) Wages, benefits and fees, net:

- Includes salaries and short-term incentive cash-based compensation paid to Dan Blondal, CEO; Stephen Campbell, CTO; Alex Holmes, COO; Carlo Valente, CFO; Denis Geoffroy, Chief Commercialization Officer (CCO); Adam Johnson, Senior Vice-President of External Affairs; Kelli Forster, Senior Vice-President of People & Culture; and Leanne Swanson, Corporate Secretary.
- Includes the services of Bedrock Capital Corp. ("Bedrock Capital") a company controlled by Paul Matysek the Executive Chairman and a Director of the Company.
- Includes compensation to non-executive directors of the Company and committee chairpersons.
- Includes the services of Donaldson Brohman Martin, CPA Inc. ("DBM CPA") to January 15, 2024, a firm in which Dan Martino, former CFO, is a principal and has significant influence. On January 15, 2024, the Company announced the appointment of Carlo Valente as the new CFO. Dan Martino remains with the Company as Vice President of Finance provided services through DBM CPA. From January 15, 2024 to June 30, 2024, salaries and short-term incentive cash-based compensation paid or accrued for Carlo Valente are included within wages, benefits, and fees.
- As of January 15, 2024, Pamela Kinsman, Corporate Secretary & Director of Sustainability resigned as Corporate Secretary and remains with the Company as Director of Sustainability. As of January 15, 2024, Leanne Swanson was appointed Corporate Secretary of the Company.

Notes to the Condensed Interim Consolidated Financial Statements

Unaudited – Prepared by Management

(Expressed in Canadian Dollars)

For the six months ended June 30, 2024 and June 30, 2023

9. RELATED PARTY TRANSACTIONS (continued)

(c) Share-based payments:

- Includes amounts recognized on vesting of stock options and Equity Incentives granted to directors and
 officers.
- During the six months ended June 30, 2024, the Company granted 175,435 RSUs to Company directors and officers (2023 – 311,784 RSUs and DSUs granted). See Note 8 for specifics on vesting terms.
- During the six months ended June 30, 2024, the Company granted 943,948 stock options to Company officers (2023 – nil). See Note 8 for specifics on vesting terms.

10. SUPPLEMENTAL CASH FLOW INFORMATION

Changes in non-cash operating working capital during the six months ended June 30, 2024 and June 30, 2023, were comprised of the following:

	June 30,	June 30,
	2024	2023
	\$	\$
Receivables and prepayments	(376,498)	1,215,020
Inventory	294,842	(393,705)
Accounts payable and accrued liabilities	929,987	1,695,918
Accounts payable to related parties	(25,611)	7,766
Deferred liabilities	-	1,545,338
Net change	822,720	4,070,337

The Company incurred non-cash investing and financing activities during the six months ended June 30, 2024 and June 30, 2023 as follows:

	June 30, 2024 \$	June 30, 2023 \$
Non-cash investing activities:		
Property, plant and equipment included in accounts payable and accrued liabilities	96,658	1,521,807
Non-cash financing activities:		
Addition of right-of-use asset	-	411,800

During the six months ended June 30, 2024 and June 30, 2023, no amounts were paid for interest or income taxes. Cash and cash equivalents consist of the following:

	June 30,	December 31,
	2024	2023
	\$	\$
Cash	4,029,504	6,241,778
Cash equivalents	11,113,339	25,627,104
Cash and cash equivalents, end of period/year	15,142,843	31,868,882

Restricted cash

On December 12, 2023, the Company executed certain agreements with a Canadian chartered bank to purchase a standby letter of credit for \$575,000 (the "letter of credit"). The letter of credit restricts the Company's access to the cash in respect of an executed agreement with an arm's length vendor for engineering services. The letter of credit takes the form of a redeemable guaranteed investment certificate with a one-year term maturing on December 6, 2024 and bearing interest at a rate of 4.9% per annum. The contract with the vendor concludes on August 31, 2024, at which time at the direction of the Company, the letter of credit will be redeemed.

Notes to the Condensed Interim Consolidated Financial Statements

Unaudited - Prepared by Management

(Expressed in Canadian Dollars)

For the six months ended June 30, 2024 and June 30, 2023

11. MANAGEMENT OF CAPITAL

The Company considers its capital structure to consist of its components of shareholders' equity. When managing capital, the Company's objective is to ensure that it continues as a going concern, to ensure it has sufficient capital to deploy on new and existing projects including its commercialization objectives, as well as generating returns on excess funds while maintaining liquidity/accessibility to such funds. To facilitate the management of its capital requirements, the Company prepares annual operating and capital expenditure budgets that are monitored for variances and updated regularly depending on various factors, including but not limited to: business development and commercial arrangements, capital deployment, personnel planning, service contracts with vendors, access to financing, government program applications, and general capital market or industry conditions. The Board of Directors relies on the expertise of the Company's management to sustain future development of the business towards production and licensing. Management reviews and adjusts its capital structure on an ongoing basis.

The Company is not subject to any externally imposed capital requirements. There were no changes to the Company's approach to capital management during the six months ended June 30, 2024.

The Company currently has no source of revenues, though it receives funding from government programs (Note 7) and has historically relied upon equity financing (strategic partners and capital markets) to fund its activities. In order to fund ongoing capital and operating expenditures, the Company will spend its existing working capital and will require additional capital sources.

The Company currently invests excess capital in high-interest savings accounts ("HISAs") and/or HISA funds which bear interest at variable rates (cash equivalents), as well as in guaranteed investment certificates ("GICs") bearing fixed rates of interest that are liquid and redeemable on demand (cash equivalents) and have original terms not exceeding 12 months. In specific circumstances the Company will invest in a GIC relating to standby letter of credit arrangements (restricted cash).

As at June 30, 2024 and December 31, 2023, the Company had excess capital invested in a HISA, a HISA fund, and GICs, which facilitates the diversification of treasury amongst high-credit quality Canadian chartered banks. These holdings are accessible on demand or cashable (except for restricted cash). During the six months ended June 30, 2024, the Company earned interest income of \$559,748 (2023 - \$819,874) from its treasury investments.

12. FINANCIAL INSTRUMENTS

Financial instruments - fair value

Financial instruments measured at fair value are classified into one of three levels in the fair value hierarchy according to the relative reliability of the inputs used to estimate the fair values. The three levels of the fair value hierarchy are:

- Level 1 Unadjusted quoted prices in active markets for identical assets or liabilities;
- Level 2 Inputs other than quoted prices that are observable for the assets or liability either directly or indirectly; and
- Level 3 Inputs that are not based on observable market data.

Financial instruments - classification

Financial assets:	Classification and measurement:
Cash and cash equivalents	Amortized cost
Restricted cash	Amortized cost
Receivables	Amortized cost
Deposits	Amortized cost
Financial liabilities:	Classification and measurement:
Accounts payable and accrued liabilities	Amortized cost
Accounts payable to related parties	Amortized cost
Lease liabilities	Amortized cost

Notes to the Condensed Interim Consolidated Financial Statements

Unaudited - Prepared by Management

(Expressed in Canadian Dollars)

For the six months ended June 30, 2024 and June 30, 2023

12. FINANCIAL INSTRUMENTS (continued)

Financial instruments – risk (continued)

The Company's financial instruments measured at amortized cost approximate their fair values. The carrying value of lease liabilities approximates fair value due to being discounted with a rate of interest that approximates market rates.

Financial instruments - risk

The Company's financial instruments can be exposed to certain financial risks including liquidity risk, interest rate risk, credit risk, price risk, and currency risk.

a) Liquidity risk

Liquidity risk is the risk that the Company will be unable to meet its financial obligations as they come due. The Company has historically relied upon government assistance programs, equity financings, and the exercise of convertible equity securities (options and warrants), to satisfy its capital requirements and will continue to depend upon these and other possible sources of capital to finance its activities until such time that the Company generates profitability and positive operating cash flows.

b) Interest rate risk

The Company is exposed to interest rate risk because of fluctuating interest rates. The Company's exposure to variable interest rates is limited to cash and cash equivalents held in its HISA and HISA fund, and deposits held as collateral with a Canadian chartered bank on the Company's corporate credit cards. The Company's GICs carry fixed rates of interest.

For the six months ended June 30, 2024, every 1% fluctuation in interest rates would have impacted loss and comprehensive loss for the period by approximately \$101,000 (2023 – \$165,000).

c) Credit risk

Credit risk is the risk of potential loss to the Company if the counterparty to a financial instrument fails to meet its contractual obligations. The Company is exposed to credit risk on its cash and cash equivalents, restricted cash, receivables, and deposits.

The Company minimizes its credit risk on its cash and cash equivalents and restricted cash (standby letter of credit), by holding the funds with high-credit quality Canadian chartered banks. Management believes that the Company's credit risk attributable to its various components of receivables is low.

The Company is exposed to credit risk relating to its deposits (security deposits on facilities and other collateral), in which management believes the risk to be low. The Company's deposits are subject to the expected credit loss model for impairment testing. The Company applies the IFRS 9 simplified approach to the deposits to measure expected credit loss which uses a lifetime expected loss allowance. The deposits have been assessed based on debtor circumstances and are considered to be low risk. The Company believes its exposure to credit risk is low with respect to accrued government assistance, and sales tax recoverable as these amounts are due from the Government of Canada.

d) Price risk

Equity price risk is defined as the potential adverse impact on the Company's results of operations and the ability to obtain equity financing, or the ability of holders of convertible equity securities (options and warrants) to exercise their securities, which affects proceeds to the Company on such exercises, due to movements in individual equity prices or general movements in the level of the stock market. The Company closely monitors individual equity movements to determine the appropriate course of action to be taken by the Company.

Commodity price risk is defined as the potential adverse impact on the Company's results of operations in respect of fluctuating prices of its raw materials inventory. The Company is exposed to commodity price risk including exposure to the fluctuating market prices of lithium as it relates to lithium raw materials within inventory. Adjustments to the Company's lithium inventory in respect of market fluctuations are included within research and operational expenses, net.

Notes to the Condensed Interim Consolidated Financial Statements

Unaudited – Prepared by Management

(Expressed in Canadian Dollars)

For the six months ended June 30, 2024 and June 30, 2023

12. FINANCIAL INSTRUMENTS (continued)

Financial instruments - risk (continued)

e) Currency risk

Currency risk is the risk of fluctuation in profit or loss that arises from fluctuations in foreign exchange rates and the degree of volatility of those rates. The Company is exposed to currency risk as it incurs certain transactions in United States dollar, the Euro, and the British Pound. Additionally, as at June 30, 2024, the Company held certain financial assets and liabilities that were denominated in these foreign currencies. Based on the June 30, 2024 value of net assets denominated in foreign currencies, the impact of a 10% fluctuation in foreign exchange rates relative to the Canadian dollar would impact loss and comprehensive loss for the period by approximately \$26,000 (2023 - \$30,000).

13. SEGMENTED INFORMATION

The Company's cathode active materials (CAM) manufacturing business is organized into two segments being a research and innovation operation, and a piloting and pre-commercialization operation. The Company's chief operating decision maker reviews the operating results, cash flows, and assesses capital expenditure plans and forecasts and makes capital allocation decisions for each of the two operating locations. The Company's non-current assets are located in Canada with the exception of certain patents (intangible assets) that are issued from patent regulators in foreign jurisdictions (Note 6). Segment performance is evaluated based on a number of measures including operating expenses, working capital and liabilities, and cash flows from operating and investing activities. Certain costs are managed on a consolidated basis and are therefore not reflected in segment income.

Consolidated statements of loss and comprehensive loss information	Research and innovation	Piloting and pre- commercialization	Consolidated
	June 30, 2024	June 30, 2024	June 30, 2024
Three months ended	\$	\$	\$
Expenses			
Amortization and depreciation	63,459	5,359	68,818
Business development and professional fees	30,238	148,825	179,063
General and administrative and finance costs	260,201	316,546	576,747
Interest and other income	(206,603)	(41,514)	(248,117)
Research and operational expenses, net	328,102	2,118,616	2,446,718
Wages, benefits and fees, net	1,906,196	1,361,125	3,267,321
Segment loss	(2,381,593)	(3,908,957)	(6,290,550)
Corporate expenses			(663,416)
General and administrative expenses			(115,952)
Corporate wages, benefits and fees			(896,769)
Share-based payments			(403,093)
Loss and comprehensive loss for the period			(8,369,780)

Consolidated statements of loss and comprehensive loss information	Research and innovation	Piloting and pre- commercialization	Consolidated
	June 30,	June 30,	June 30.
	2023	2023	2023
Three months ended	\$	\$	\$
Expenses			
Amortization and depreciation	60,545	1,675	62,220
Business development and professional fees	79,730	11,321	91,051
General and administrative and finance costs	301,559	154,351	455,910
Interest (income) and loss on disposal of equipment	(401,793)	964	(400,829)
Research and operational expenses, net	456,603	1,597,702	2,054,305
Wages, benefits and fees, net	1,648,004	1,688,051	3,336,055
Segment loss	(2,144,648)	(3,454,064)	(5,598,712)
Corporate expenses			(763,080)
General and administrative expenses			(190,109)
Corporate wages, benefits and fees, net			(690,017)
Share-based payments			(445,824)
Consolidated loss and comprehensive loss for the period			(7,687,742)

Notes to the Condensed Interim Consolidated Financial Statements

Unaudited – Prepared by Management

(Expressed in Canadian Dollars)

For the six months ended June 30, 2024 and June 30, 2023

13. SEGMENTED INFORMATION (continued)

Consolidated statements of loss and comprehensive loss information	Research and innovation	Piloting and pre- commercialization	Consolidated
	June 30,	June 30,	June 30,
Six months ended	2024 \$	2024 \$	2024 \$
Expenses	,	· · · · · · · · · · · · · · · · · · ·	· · · · · · · · · · · · · · · · · · ·
Amortization and depreciation	126,567	9,214	135,781
Business development and professional fees	75,689	174,892	250,581
General and administrative and finance costs	516,166	527,025	1,043,191
Interest and other income	(544,734)	(66,400)	(611,134)
Research and operational expenses, net	777,864	4,288,948	5,066,812
Wages, benefits and fees, net	4,010,105	3,392,516	7,402,621
Segment loss	(4,961,657)	(8,326,195)	(13,287,852)
Corporate expenses			(1,272,511)
General and administrative expenses			(393,328)
Corporate wages, benefits and fees			(1,773,273)
Share-based payments			(1,668,806)
Loss and comprehensive loss for the period			(18,395,770)

Consolidated statements of loss and comprehensive loss information	Research and innovation	Piloting and pre- commercialization	Consolidated
	June 30,	June 30,	June 30,
	2023	2023	2023
Six months ended	\$	\$	\$
Expenses			
Amortization and depreciation	117,934	3,106	121,040
Business development and professional fees	215,841	15,733	231,574
General and administrative and finance costs	552,414	366,591	919,005
Interest (income) and loss on disposal of equipment	(819,039)	9,951	(809,088)
Research and operational expenses, net	855,110	3,144,271	3,999,381
Wages, benefits and fees, net	3,619,364	3,175,523	6,794,887
Segment loss	(4,541,624)	(6,715,175)	(11,256,799)
Corporate expenses			(1,370,845)
General and administrative expenses			(419,824)
Corporate wages, benefits and fees, net			(2,049,104)
Share-based payments			(667,274)
Consolidated loss and comprehensive loss for the period			(15,763,846)

Notes to the Condensed Interim Consolidated Financial Statements

Unaudited – Prepared by Management

(Expressed in Canadian Dollars)

For the six months ended June 30, 2024 and June 30, 2023

13. SEGMENTED INFORMATION (continued)

Consolidated statements of cash flows information	Research and innovation	Piloting and pre- commercialization	Consolidated
	June 30, 2024	June 30, 2024	June 30, 2024
For the six months ended	\$	\$	\$
Segment operating cash flows	(4,477,877)	(7,779,586)	(12,257,463)
Other operating cash flows			(3,334,645)
Cash used in operating activities			(15,592,108)
Investing activities			
Interest income received on cash and cash equivalents	544,734	15,014	559,748
Deposits and purchases of property, plant and equipment, net	(158,998)	(1,266,186)	(1,425,184)
Payments for intangible assets	(6,959)	-	(6,959)
Cash used in investing activities	378,777	(1,251,172)	(872,395)
Financing activities			
Issuance of common shares for cash	-	-	-
Payments of lease liabilities	(261,536)	-	(261,536)
Cash provided by financing activities	(261,536)	-	(261,536)
Change in cash and cash equivalents			(16,726,039)
Cash and cash equivalents, beginning of period			31,868,882
Cash and cash equivalents, end of period			15,142,843
Cash and Cash equivalents, end of period			
Consolidated statements of cash flows information	Research and innovation	Piloting and pre- commercialization	Consolidated
		• .	Consolidated June 30,
Consolidated statements of cash flows information	innovation	commercialization	
	innovation June 30,	commercialization June 30,	June 30,
Consolidated statements of cash flows information	innovation June 30, 2023	June 30, 2023	June 30, 2023 \$
Consolidated statements of cash flows information For the six months ended	innovation June 30, 2023 \$	commercialization June 30, 2023 \$	June 30, 2023
Consolidated statements of cash flows information For the six months ended Segment operating cash flows	innovation June 30, 2023 \$	commercialization June 30, 2023 \$	June 30, 2023 \$ (7,261,561) (3,839,773)
Consolidated statements of cash flows information For the six months ended Segment operating cash flows Other operating cash flows	innovation June 30, 2023 \$	commercialization June 30, 2023 \$	June 30, 2023 \$ (7,261,561) (3,839,773)
Consolidated statements of cash flows information For the six months ended Segment operating cash flows Other operating cash flows Cash used in operating activities	innovation June 30, 2023 \$	commercialization June 30, 2023 \$	June 30, 2023 \$ (7,261,561) (3,839,773)
Consolidated statements of cash flows information For the six months ended Segment operating cash flows Other operating cash flows Cash used in operating activities Investing activities	innovation June 30, 2023 \$ (4,865,139)	commercialization June 30, 2023 \$	June 30, 2023 \$ (7,261,561) (3,839,773) (11,101,334)
Consolidated statements of cash flows information For the six months ended Segment operating cash flows Other operating cash flows Cash used in operating activities Investing activities Interest income received on cash and cash equivalents	innovation June 30, 2023 \$ (4,865,139)	commercialization June 30, 2023 \$ (2,396,422)	June 30, 2023 \$ (7,261,561) (3,839,773) (11,101,334) 819,874 (1,342,932)
Consolidated statements of cash flows information For the six months ended Segment operating cash flows Other operating cash flows Cash used in operating activities Investing activities Interest income received on cash and cash equivalents Deposits and purchases of property, plant and equipment, net	innovation June 30, 2023 \$ (4,865,139) 819,874 (329,742)	commercialization June 30, 2023 \$ (2,396,422)	June 30, 2023 \$ (7,261,561) (3,839,773) (11,101,334)
Consolidated statements of cash flows information For the six months ended Segment operating cash flows Other operating cash flows Cash used in operating activities Investing activities Interest income received on cash and cash equivalents Deposits and purchases of property, plant and equipment, net Payments for intangible assets	innovation June 30, 2023 \$ (4,865,139) 819,874 (329,742) (4,231)	commercialization June 30, 2023 \$ (2,396,422)	June 30, 2023 \$ (7,261,561) (3,839,773) (11,101,334) 819,874 (1,342,932) (4,231)
Consolidated statements of cash flows information For the six months ended Segment operating cash flows Other operating cash flows Cash used in operating activities Investing activities Interest income received on cash and cash equivalents Deposits and purchases of property, plant and equipment, net Payments for intangible assets Cash used in investing activities	innovation June 30, 2023 \$ (4,865,139) 819,874 (329,742) (4,231)	commercialization June 30, 2023 \$ (2,396,422)	June 30, 2023 \$ (7,261,561) (3,839,773) (11,101,334) 819,874 (1,342,932) (4,231)
Consolidated statements of cash flows information For the six months ended Segment operating cash flows Other operating cash flows Cash used in operating activities Investing activities Interest income received on cash and cash equivalents Deposits and purchases of property, plant and equipment, net Payments for intangible assets Cash used in investing activities Financing activities	innovation June 30, 2023 \$ (4,865,139) 819,874 (329,742) (4,231) 485,901	commercialization June 30, 2023 \$ (2,396,422)	June 30, 2023 \$ (7,261,561) (3,839,773) (11,101,334) 819,874 (1,342,932) (4,231) (527,289)
Consolidated statements of cash flows information For the six months ended Segment operating cash flows Other operating cash flows Cash used in operating activities Investing activities Interest income received on cash and cash equivalents Deposits and purchases of property, plant and equipment, net Payments for intangible assets Cash used in investing activities Financing activities Issuance of common shares for cash	innovation June 30, 2023 \$ (4,865,139) 819,874 (329,742) (4,231) 485,901	commercialization June 30, 2023 \$ (2,396,422)	June 30, 2023 \$ (7,261,561) (3,839,773) (11,101,334) 819,874 (1,342,932) (4,231) (527,289)
Consolidated statements of cash flows information For the six months ended Segment operating cash flows Other operating cash flows Cash used in operating activities Investing activities Interest income received on cash and cash equivalents Deposits and purchases of property, plant and equipment, net Payments for intangible assets Cash used in investing activities Financing activities Issuance of common shares for cash Payments of lease liabilities Cash provided by financing activities	innovation June 30, 2023 \$ (4,865,139) 819,874 (329,742) (4,231) 485,901 6,777,245 (190,880)	commercialization June 30, 2023 \$ (2,396,422) (1,013,190) (1,013,190)	June 30, 2023 \$ (7,261,561) (3,839,773) (11,101,334) 819,874 (1,342,932) (4,231) (527,289) 6,777,245 (190,880) 6,586,365
Consolidated statements of cash flows information For the six months ended Segment operating cash flows Other operating cash flows Cash used in operating activities Investing activities Interest income received on cash and cash equivalents Deposits and purchases of property, plant and equipment, net Payments for intangible assets Cash used in investing activities Financing activities Issuance of common shares for cash Payments of lease liabilities	innovation June 30, 2023 \$ (4,865,139) 819,874 (329,742) (4,231) 485,901 6,777,245 (190,880)	commercialization June 30, 2023 \$ (2,396,422) (1,013,190) (1,013,190)	June 30, 2023 \$ (7,261,561) (3,839,773) (11,101,334) 819,874 (1,342,932) (4,231) (527,289) 6,777,245 (190,880)

Notes to the Condensed Interim Consolidated Financial Statements

Unaudited – Prepared by Management (Expressed in Canadian Dollars)

For the six months ended June 30, 2024 and June 30, 2023

14. SUBSEQUENT EVENTS

- (a) On August 1, 2024, the Company granted 369,564 RSUs and DSUs in aggregate to Directors of the Company following the results of the Annual General and Special Meeting held on August 1, 2024. The 326,086 DSUs vested immediately on grant, and the 43,478 RSUs vest in three annual instalments (one-third (14,493) on August 1, 2025; one-third (14,493) on August 1, 2026; and the final one-third (14,492) on August 1, 2027).
- (b) On August 12, 2024, the Company reached a definitive agreement to sell a vacant 157,000 sq. ft. parcel of its land in Candiac for \$5,000,000 in gross proceeds. The purchaser has provided a deposit of \$500,000 (received) that is non-refundable except in the unlikely event that the Deed of Sale is not executed due to a fault or negligence of the Company. The parties will work in good faith to close the transaction by September 12, 2024. As at June 30, 2024, the land had a carrying value of \$3,263,658.
- (c) On August 13, 2024, the Company and Worley Chemetics (a wholly owned Canadian subsidiary of Worley Limited) announced the award of approximately \$2,000,000 and \$800,000 respectively (\$2,800,000 in total) in non-dilutive and non-repayable funding by Next Generation Manufacturing Canada (NGen) through its Electric Vehicle Manufacturing Program (EVMP). The funding stream is through to March 31, 2028.